1.70
0.02 (1.49%)
| Previous Close | 1.68 |
| Volume | 238 |
| Price / Sales | 267.00 |
| Price / Book | 0.660 |
| 52 Weeks Range |
| Operating Margin (TTM) | -173,463.83% |
| Diluted EPS (TTM) | -4.34 |
| Quarterly Revenue Growth (YOY) | -94.10% |
| Total Debt/Equity (MRQ) | 7.00% |
| Current Ratio (MRQ) | 19.49 |
| Operating Cash Flow (TTM) | -5.16 M |
| Levered Free Cash Flow (TTM) | -3.50 M |
| Return on Assets (TTM) | -43.94% |
| Return on Equity (TTM) | -81.24% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Cardio Diagnostics Holdings Inc | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -0.4 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Relative Valuation | NA |
| Financial Health | 0.0 |
| Macro Environment | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -0.31 |
Select this tab to load the latest available analysis.
|
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 7.55% |
| % Held by Institutions | 4.86% |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |